EN | SE Contact us Careers


May 4-6, 2021, 32nd Annual Cancer Progress Conference, Online

May 11, 2021, Redeye Investor Online Forum, Online

May 17-19, 2021, Bio€quity Europe, Online

May 26-27, 2021, BioStock Life Science Spring Summit, Online


Other news

Pareto Securities - interview with CEO Martin Welschof, March 3, 2021 > Link

Healthcare Direct, CEO interview, February 25, 2021 > Link

Annual General Meeting, April 29, 2021 > Link

BioInvent KOL Call: BI-1206 for Relapsed or Refractory NHL, 28 January at 11.30 am EST
> Replay
> Download pdf

1907 FP Imonc


BioInvent’s primary goal is to develop next generation immuno-oncology drugs with a focus on improving therapeutic results in areas with significant unmet need.




BioInvent’s strategy is to leverage its expertise in immunology, cancer biology and antibody biology to develop cancer immunotherapies to improve the quality of life for cancer patients. This is accomplished through collaborations with pharmaceutical companies, academic research groups, networks of clinical specialists and research foundations. The goal is to create value for the Company’s shareholders based on successful drug development and subsequent revenue streams from existing and future commercial partners.


Our tools for successful drug development



In an automated process, we select optimal antibodies for new drug candidates from our own antibody library – one of the largest in the world.


Our unique and patented screening-platform has the advantage of simultaneously identifying disease-associated targets and antibodies that bind to them.


Our cGMP certified manufacturing site provides antibodies for in-house project development, as well as for external customers.


  • +/-
  • +/-
  • Opening price
  • Bid
  • Ask
  • High
  • Low
  • Volume
  • Turnover
  • Updated